Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Astrocytes, which are homeostatic cells of the central nervous system (CNS), display
remarkable heterogeneity in their morphology and function. Besides their physical and …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease.
Phosphorylated tau accumulation causes synaptic impairment, neuronal dysfunction and …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Predicting the function of noncoding variation is a major challenge in modern genetics. In
this study, we used massively parallel reporter assays to screen 5706 variants identified …

Rapidly progressive Alzheimer's disease (rpAD) is a particularly aggressive form of
Alzheimer's disease, with a median survival time of 7–10 months after diagnosis. Why these …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently affects
36 million people worldwide with no effective treatment available. Development of AD …

Microglia, the resident immune cells of the brain, have important roles in brain health.
However, little is known about the regulation and consequences of microglial activation in …

Although the genetic causes for several rare, familial forms of Alzheimer's disease (AD) have
been identified, the etiology of the sporadic form of AD remains unclear. Here, we report a …